Staff Reports
The surprise, or maybe not-so-surprise, news this week is that FDA Commissioner Marty Makary resigned as reports swirled that President Donald Trump was preparing to fire him. The resignation was circulated publicly by the president, and Deputy Commissioner for Food Kyle Diamantas will take the helm in an acting role. For anyone following the drama at the Food and Drug Administration, this feels like the end of a messy chapter and the start of a very watchful one.
Resignation followed reports the White House was ready to pull the plug
Reporters had been saying for days that the White House had signed off on a plan to remove Makary. Those reports pushed the matter from rumor to reality, and Makary’s resignation arrived as the predictable curtain call. President Trump told reporters that Makary “was having some difficulty” and called him “a terrific guy” while confirming the change. The handoff to Acting Commissioner Kyle Diamantas is practical, but it leaves big questions about how policy and staff morale will be steadied at the FDA.
Makary’s claims of accomplishment versus the agency’s shakeup
Makary pushed back in his resignation message, saying he delivered “50 major FDA reforms” — faster drug reviews, new guidance on psychedelics, a rare-disease pathway and changes to estrogen labeling among them. HHS Secretary Robert F. Kennedy Jr. praised him for challenging the status quo. Fine. Reforms are laudable. But reforms that alienate staff, trigger leadership churn and leave the agency scrambling are not a victory lap — they’re a warning light. If you announced 50 reforms but lost the confidence of your own team, you didn’t overhaul the place so much as break its rhythm.
What to watch next: mifepristone, approvals, and agency credibility
The immediate policy flashpoints haven’t gone away. The much-discussed safety review of the abortion drug mifepristone, questions about the pace and predictability of drug approvals, and disputes over vaping and flavored e-cigarette rules will all land on Kyle Diamantas’s desk. That’s a heavy lift for an acting boss. The FDA needs stability and clear scientific standards, not more headlines. The White House and Congress should be pushing for a leader who can both drive reform and keep career scientists and staff on board — because reform without credibility is just chaos with a press release.
Make no mistake: this resignation was the result of a clash between an activist leadership agenda and the ugly realities of running a large regulatory agency. President Trump owes his team competent appointees who can execute and unite, and the FDA deserves a leader who can do both. Expect scrutiny from Capitol Hill and plenty of interest groups leaning in. For now, the agency is in transition — and the American public should demand that transition produces substance, not spectacle.
